Barclays Maintains Overweight on Omada Health, Lowers Price Target to $24
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and lowers the price target from $27 to $24.
Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and lowers the price target from $27 to $24.
